Next, we develop a treatment strategy involving inhibition of ETAR with macitentan, an ETAR antagonist approved for treatment of pulmonary hypertension, and re-expression of the ETBR gene with adenoviral gene therapy. The gene discussed is EDNRA; the disease is pulmonary hypertension.